^
    Back
    Association details:
    Biomarker:TP53 deletion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Istodax (romidepsin) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2022
    Title:

    1356 Histone Deacetylase Inhibition Restores Therapy Response in TP53mutated Acute Lymphoblastic Leukemia to Chemotherapy

    Published date:
    11/03/2022
    Excerpt:
    ...preliminary mouse experiments using TP53 deleted RCH-ACV cells showed that romidepsin improves the response to cytarabine in TP53 aberrant leukemia in vivo...Romidepsin can restore response to therapy in TP53 deleted ALL, presumably by reactivation of p53 target genes in response to cellular stress. Therefore, romidepsin may be used to improve therapy response in relapsed TP53 deleted ALL.
    DOI:
    https://doi.org/10.1182/blood-2022-157118